Chemotherapy response rates among patients with endometrial cancer who have elevated serum platelets

Nora T. Kizer, Hatem Hatem, Elizabeth K. Nugent, Gongfu Zhou, Kathleen Moore, Paul Heller, David G. Mutch, Premal H. Thaker

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer. Methods From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 109/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ2 Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival. Results There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56-1.88, P = 0.93). Conclusions Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 109/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.

Original languageEnglish (US)
Pages (from-to)1015-1022
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume25
Issue number6
DOIs
StatePublished - Jul 11 2015

Fingerprint

Endometrial Neoplasms
Platelet Count
Blood Platelets
Drug Therapy
Serum
Confidence Intervals
Disease-Free Survival
Carcinosarcoma
Recurrence
Survival
Proportional Hazards Models
Disease Progression
Histology
Reference Values
Multivariate Analysis
Retrospective Studies
Students
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Kizer, Nora T. ; Hatem, Hatem ; Nugent, Elizabeth K. ; Zhou, Gongfu ; Moore, Kathleen ; Heller, Paul ; Mutch, David G. ; Thaker, Premal H. / Chemotherapy response rates among patients with endometrial cancer who have elevated serum platelets. In: International Journal of Gynecological Cancer. 2015 ; Vol. 25, No. 6. pp. 1015-1022.
@article{8942e693e26c4baab61ea716371989ab,
title = "Chemotherapy response rates among patients with endometrial cancer who have elevated serum platelets",
abstract = "Objective This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer. Methods From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 109/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ2 Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival. Results There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7{\%}) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95{\%} 95{\%} confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95{\%} CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95{\%} CI, 0.56-1.88, P = 0.93). Conclusions Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 109/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.",
author = "Kizer, {Nora T.} and Hatem Hatem and Nugent, {Elizabeth K.} and Gongfu Zhou and Kathleen Moore and Paul Heller and Mutch, {David G.} and Thaker, {Premal H.}",
year = "2015",
month = "7",
day = "11",
doi = "10.1097/IGC.0000000000000453",
language = "English (US)",
volume = "25",
pages = "1015--1022",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Chemotherapy response rates among patients with endometrial cancer who have elevated serum platelets. / Kizer, Nora T.; Hatem, Hatem; Nugent, Elizabeth K.; Zhou, Gongfu; Moore, Kathleen; Heller, Paul; Mutch, David G.; Thaker, Premal H.

In: International Journal of Gynecological Cancer, Vol. 25, No. 6, 11.07.2015, p. 1015-1022.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy response rates among patients with endometrial cancer who have elevated serum platelets

AU - Kizer, Nora T.

AU - Hatem, Hatem

AU - Nugent, Elizabeth K.

AU - Zhou, Gongfu

AU - Moore, Kathleen

AU - Heller, Paul

AU - Mutch, David G.

AU - Thaker, Premal H.

PY - 2015/7/11

Y1 - 2015/7/11

N2 - Objective This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer. Methods From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 109/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ2 Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival. Results There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56-1.88, P = 0.93). Conclusions Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 109/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.

AB - Objective This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer. Methods From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 109/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ2 Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival. Results There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46-5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26-3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56-1.88, P = 0.93). Conclusions Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 109/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.

UR - http://www.scopus.com/inward/record.url?scp=84936929194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936929194&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000453

DO - 10.1097/IGC.0000000000000453

M3 - Article

C2 - 26098089

AN - SCOPUS:84936929194

VL - 25

SP - 1015

EP - 1022

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -